ERBB3 and neoplasm: Because it lacks inherent kinase activity, targeting HER3 is not an efficient method to employ for signal inhibition [94,95]; however, increased HER3 on resistant tumor cells allows for missile-like tumor homing by nanocarriers such as HPK [21,22,23].